Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + tiragolumab + zanzalintinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Atezolizumab + tiragolumab + zanzalintinib** is an investigational combination regimen for the treatment of solid tumors, consisting of three distinct agents: - **Atezolizumab**: A monoclonal antibody immune checkpoint inhibitor targeting PD-L1, blocking its interaction with PD-1 and B7.1 to enhance T cell activity against tumors. - **Tiragolumab**: A monoclonal antibody immune checkpoint inhibitor targeting TIGIT, a receptor on immune cells that negatively regulates immune function, thereby promoting antitumor immunity. - **Zanzalintinib (XL092)**: A third-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET, and TAM kinases (TYRO3, AXL, MER) involved in tumor angiogenesis, metastasis, and immunosuppression. The regimen is under investigation primarily for non-clear-cell renal cell carcinoma (nccRCC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN). Zanzalintinib demonstrates synergistic effects with immune checkpoint inhibitors due to its immunomodulatory properties[1][3]. Clinical trials have confirmed the tolerability and rationale for such combinations, potentially addressing unmet needs and broadening treatment options in advanced solid tumors[3].
- Brand names
- Tecentriq (atezolizumab)
- Other names
- atezolizumab + tiragolumab + zanzalintinib
02
Targets
AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)TIGIT (T cell immunoreceptor with Ig and ITIM domains)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + tiragolumab + zanzalintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + tiragolumab + zanzalintinib.